Longaeva Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15M Buy
30,279
+5,344
+21% +$2.37M 0.33% 87
2026
Q1
$11.1M Buy
+24,935
New +$11.6M 0.41% 64

Other funds holding VRTX

Longaeva Partners's VRTX Position: Q2 2026 in Review

Longaeva Partners increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q2 2026, buying an estimated $2.37M and bringing the position to 30,279 shares worth $15M. The position accounts for 0.33% of the portfolio, ranked #87.

Longaeva Partners first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Longaeva Partners held 30,279 shares of Vertex Pharmaceuticals worth $15M as of Q2 2026.
  • Longaeva Partners bought 5,344 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.37M.
  • Vertex Pharmaceuticals made up 0.33% of Longaeva Partners's portfolio in Q2 2026, its #87 holding.
  • Longaeva Partners first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.